Human Immunodeficiency Virus 
Welcome,         Profile    Billing    Logout  

503 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Human Immunodeficiency Virus
NCT02500849: Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients

Active, not recruiting
1
12
US
SB-728mR-HSPC Infusion 3 days following busulfan conditioning, busulfan
City of Hope Medical Center, Sangamo Therapeutics, California Institute for Regenerative Medicine (CIRM)
HIV
09/20
08/24
2021-000436-62: This study will evaluate the relative bioavailability of the B/F/TAF tablet for oral suspension formulation compared to the adult-strength B/F/TAF tablet and will inform on appropriateness of this formulation for future clinical studies in children with HIV.

Not yet recruiting
1
198
US
Biktarvy, Emtricitabine/Tenofovir Alafenamide, B/F/TAF, F/TAF, Film-coated tablet, Tablet, Biktarvy
Gilead Sciences, Inc, Gilead Sciences, Inc
Human Immunodeficiency Virus (HIV-1) Infection, Human Immunodeficiency Virus (HIV-1) Infection, Diseases [C] - Virus Diseases [C02]
 
 
BEAT-2, NCT03588715: Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074

Active, not recruiting
1
15
US
Pegylated Interferon alpha 2b (peg-IFN-α2b), Pegintron, 3BNC117 + 10-1074, Broadly Neutralizing Antibodies
Luis Montaner, University of Pennsylvania, Philadelphia Fight, Rockefeller University, Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID)
HIV, HIV/AIDS, HIV-1 Infection
12/21
10/22
NCT05141422: A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers

Active, not recruiting
1
20
RoW
SHR2150 tablet、efavirenz
Jiangsu HengRui Medicine Co., Ltd.
Human Immunodeficiency Virus Infection
01/22
01/22
NCT03875209: 10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults

Completed
1
54
US
10E8.4/iMab
David Ho, Bill and Melinda Gates Foundation, International AIDS Vaccine Initiative, The Emmes Company, LLC
HIV-1-infection
03/22
03/22
2021-003955-40: A study to evaluate the amount of darunavir and cobicistat in the body when taken as a combination tablet (2 drugs combined in 1 tablet) or as 2 separate drugs, with food by healthy adults

Ongoing
1
32
Europe
Darunavir/ cobicistat, Darunavir, Cobicistat, TMC114 / JNJ-48763364, TMC114, JNJ-48763364, Tablet, Oral suspension, PREZISTA©
Janssen-Cilag International NV, Janssen Research and Development, LLC
Human Immunodeficiency Virus-1 (Healthy participants), HIV-1 (Healthy participants), Diseases [C] - Virus Diseases [C02]
 
 
NCT04620304: Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients

Completed
1
15
RoW
UB-421 SC(dB4C7C22-6 mAb)
United BioPharma, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung Veterans General Hospital., Taoyuan General Hospital
HIV-1 Infection
05/22
05/22
NCT04688034: Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV With Hemophilia.

Completed
1
5
Japan
OP-724, CBP-beta-catenin inhibitor, PRI-724 (former name)
Kiminori Kimura, MD, Japan Agency for Medical Research and Development, Ohara Pharmaceutical Co., Ltd.
Liver Cirrhosis
07/22
12/22
NCT05165550: Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of Elsulfavirine and Its Active Metabolite VM-1500A in Healthy Subjects

Completed
1
24
US
Elsulfavirine, VM-1500
Viriom
HIV-1-infection
07/22
07/22
NCT04561258: Study to Evaluate the Safety of a Gene and Cell Therapy Product in Participants With HIV That is Well-Controlled on Antiretroviral Therapy

Completed
1
7
US
AGT103-T
American Gene Technologies International Inc.
HIV
08/22
11/22
UNIVERSALRBA, NCT05489406: Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS.

Completed
1
16
Europe
DTG DT (6 x 5 mg), Tivicay 5 mg (ViiV), F/TAF TOS (3 x 60/7.5 mg), F/TAF TOS 60/7.5 mg (Gilead)
Radboud University Medical Center, Gilead Sciences
Hiv
03/23
11/23
NCT03699241: A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

Completed
1
61
US, RoW
BG505 SOSIP.664 gp140, adjuvanted, Placebo
International AIDS Vaccine Initiative, GlaxoSmithKline, Fred Hutchinson Cancer Research Center - Seattle HIV Vaccine Trials Unit, Kenya AIDS Vaccine Initiative - Institute of Clinical Research (KAVI-ICR), Massachusetts General Hospital
HIV Infections
03/23
07/23
SPAN, NCT05291520: A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

Completed
1
24
US
VH3810109, rHuPH20
ViiV Healthcare
HIV Infections
04/23
04/23
NCT05393271: First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

Completed
1
73
US
VH4011499, GSK4011499, Placebo, Midazolam
ViiV Healthcare
HIV Infections
04/23
04/23
NCT04592315: A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients

Completed
1
46
RoW
Lipovirtide Injection
Shanxi Kangbao Biological Product Co., Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences
HIV Infections
05/23
07/23
NCT04484337: Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

Completed
1
138
US, RoW
Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL, Topical non-steroidal anti-inflammatory drug, Topical steroid, Placebo creams/gels, Recombinant human hyaluronidase PH20 (rHuPH20)
ViiV Healthcare
HIV Infections
05/23
05/23
NCT05349968: Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients

Completed
1
24
RoW
Lipovirtide for injection, nothing
Shanxi Kangbao Biological Product Co., Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences
HIV Infections
06/23
09/23
NCT05776108: A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation

Completed
1
24
US
Cabotegravir IR Formulation (reference), Cabotegravir DT Formulation (test 1), Cabotegravir DT Formulation (test 2)
ViiV Healthcare
HIV Infections
06/23
06/23
NCT05001373: A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Active, not recruiting
1
56
US
Core-g28v2 60mer mRNA Vaccine, eOD-GT8 60mer mRNA Vaccine
International AIDS Vaccine Initiative, ModernaTX, Inc., George Washington University, Fred Hutchinson Cancer Center, Emory University, UT Health San Antonio
Hiv
06/23
07/24
NCT05163522: First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants

Completed
1
73
US
VH4004280, GSK4004280, Placebo, Midazolam
ViiV Healthcare
HIV Infections
06/23
06/23
NCT05414786: A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)

Active, not recruiting
1
18
RoW
eOD-GT8 60mer mRNA Vaccine (100µg)
International AIDS Vaccine Initiative, AURUM Tembisa Clinical Research, Center for Family Health Research, ModernaTX, Inc.
HIV-1-infection
06/23
06/23
NCT04224701: A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

Active, not recruiting
1
48
Europe, US
BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted, Placebo
International AIDS Vaccine Initiative, GlaxoSmithKline, Rockefeller University, George Washington University, Amsterdam UMC, location VUmc
HIV Infections
08/23
12/23
NCT04554966: Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

Completed
1
54
US
ABBV-382, Placebo for ABBV-382
AbbVie
Human Immunodeficiency Virus (HIV)
08/23
08/23
NCT05631704: A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

Recruiting
1
105
US
VH4524184, Midazolam, Placebo
ViiV Healthcare
HIV Infections
08/23
08/23
NCT05933824: Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects

Recruiting
1
80
RoW
LP-98 injection, placebo-controlled
Shanxi Kangbao Biological Product Co., Ltd., Institute of Pathogen Biology, Chinese Academy of Medical Sciences
Hiv
12/23
12/23
NCT05418868: A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

Recruiting
1
60
US
Cabotegravir 200 mg/mL, Cabotegravir 400 mg/mL, Recombinant human hyaluronidase PH20 (rHuPH20)
ViiV Healthcare
HIV Infections
02/26
11/27
HVRRICANE, NCT04301154: Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth

Active, not recruiting
1
25
RoW
HIVIS DNA/MVA-CMDR, HIVIS DNA + Cervarix and MVA-CMDR, Cervarix
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bambino Gesù Hospital and Research Institute, PENTA Foundation, Johns Hopkins University, University of Miami, Leidos Biomedical Research, Inc., Case Western Reserve University, Karolinska Institutet, Walter Reed Army Institute of Research (WRAIR), Armed Forces Research Institute of Medical Sciences, Thailand, University of Padova, Chulalongkorn University
HIV Infections
10/23
02/25
NCT03174977: Pharmacokinetics Distribution of Raltegravir by PET/MR

Recruiting
1
10
US
18F-Raltegravir
University of California, San Francisco, Merck Sharp & Dohme LLC
HIV-1-infection
11/24
01/25
NCT05458102: Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

Terminated
1
18
US
Vesatolimod, GS-9620, Cobicistat, Tybost®, Voriconazole, Vfend®, Rifabutin, Mycobutin®
Gilead Sciences
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
10/23
10/23
NCT03705169: Pharmacokinetics and Safety of SAR441236

Terminated
1
52
US
SAR441236, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics
HIV-1-infection
04/22
04/22
NCT04927585: Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

Completed
1
42
US
env (A,B,C,A/E)/gag (C) DNA Vaccine, Polyvalent DNA (PDPHV-201401) Plasmid, gp120 (A,B,C,A/E) Protein Vaccine, PDPHV-201401 Recombinant Proteins gp120A, gp120B, gp120C, gp120AE, GLA-SE adjuvant, glucopyranosyl lipid adjuvant-stable emulsion, Placebo
Worcester HIV Vaccine, Brigham and Women's Hospital, Access to Advanced Health Institute (AAHI)
HIV Infections
12/23
12/23
NCT04900974: Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women

Recruiting
1
10
US
Doravirine
University of North Carolina, Chapel Hill, Merck Sharp & Dohme LLC
HIV Infections, Pregnancy Related
06/24
09/24
NCT06168318: A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants

Recruiting
1
108
Europe
VH4004280 Formulation A, VH4004280 Formulation B, VH4004280 Formulation C, VH4004280 Formulation D, VH4004280 Formulation E
ViiV Healthcare
HIV Infections
09/24
09/24
NCT05944848: A Study of CL-197 Capsules in Healthy Participants

Completed
1
44
RoW
1 mg CL-197 capsules, 10 mg CL-197 capsules or CL-197 placebo, 30 mg CL-197 capsules or CL-197 placebo, 60 mg CL-197 capsules or CL-197 placebo, 100 mg CL-197 capsules or CL-197 placebo
HeNan Sincere Biotech Co., Ltd
HIV-1
01/24
01/24
RV591, NCT06205056: Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults

Not yet recruiting
1
50
RoW
Ad26.Mos4.HIV [Arm 1], Ad26.Mos4.HIV [Arm 2], CH505 TF chTrimer+ALFQ [Arm 1], CH505 TF chTrimer+ALFQ [Arm 2], ALFQ [Arm 1], ALFQ [Arm 2]
U.S. Army Medical Research and Development Command, Janssen Vaccines & Prevention B.V., Henry M. Jackson Foundation for the Advancement of Military Medicine, Duke University, Walter Reed Army Institute of Research (WRAIR), National Institute of Allergy and Infectious Diseases (NIAID), Makerere University Walter Reed Project
Human Immunodeficiency Virus
12/24
09/25
NCT06450275: Bioequivalence Study to Compare Dolutegravir 50mg Film-coated Tablets

Completed
1
32
RoW
Dolutegravir 50 MG Film Coated Tablet, Tivicay 50mg, film-coated tablets
Humanis Saglık Anonim Sirketi
HIV Infections
01/24
03/24
NCT04826094: A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya

Completed
1
126
RoW
Env-C Plasmid DNA, HIV Env gp145 C.6980 protein, Rehydragel®, ALF43, dmLT, Placebo (IM), Placebo (TCl)
National Institute of Allergy and Infectious Diseases (NIAID), US Army Medical Research Directorate-Africa, US Military HIV Research Program, The Emmes Company, LLC, Walter Reed Army Institute of Research (WRAIR)
HIV Infections
01/24
02/24
MK-8510-002, NCT05700734: MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants

Withdrawn
1
24
NA
MK-8510
Merck Sharp & Dohme LLC
HIV-1, Human Immunodeficiency Virus 1, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
02/24
02/24
MK-8527-004, NCT05494736: MK-8527 Single-Dose Trial in HIV-1 Infected Participants

Completed
1
20
Europe, RoW
MK-8527
Merck Sharp & Dohme LLC
Human Immunodeficiency Virus
01/24
01/24
NCT05435027: Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV)

Completed
1
342
RoW
GRT-R912, samRNA-Spikebeta-TCE11, GRT-R914, samRNA-Spikebeta-TCE9, GRT-R918, samRNA-SpikeOmicron-N-TCE11
Gritstone bio, Inc.
COVID-19, SARS-CoV-2
03/24
03/24
NCT05261191: A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

Completed
1
24
US
MGD020, MGD014
MacroGenics, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services
Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
05/24
05/24
NCT05983874: A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted

Enrolling by invitation
1
8
Europe
BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage
International AIDS Vaccine Initiative, 3M, Access to Advanced Health Institute (AAHI), Polymun Scientific GmbH
Hiv
03/25
03/25
NCT06310616: A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

Recruiting
1
25
US
VH4524184, Loestrin
ViiV Healthcare
HIV Infections
08/24
08/24
NCT06310551: First Time in Human Study of Long Acting VH4524184 Formulations

Recruiting
1
72
US
Oral VH4524184, VH4524184 Formulation A SC, Placebo Formulation A SC, rHuPH20, PH20, Halozyme ENHANZE, VH4524184 Formulation B SC, Placebo Formulation B SC, VH4524184 Formulation C SC, Placebo Formulation C SC, VH4524184 Formulation A IM, Placebo Formulation A IM
ViiV Healthcare, GlaxoSmithKline
HIV Infections
03/27
01/28
NCT05416021: Relative Bioavailability Trial of Dapivirine Ring-004 and Ring-008

Active, not recruiting
1
110
RoW
dapivirine
International Partnership for Microbicides, Inc.
HIV Infections
04/24
04/24
NCT05567601: Doxil/Caelyx BE Study

Not yet recruiting
1
36
NA
DOXIL/CAELYX, doxorubicin hydrochloride liposome injection 2 mg/mL
Baxter Healthcare Corporation
Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma, Metastatic Breast Cancer
04/24
04/24
NCT06368986: A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants

Recruiting
1
36
US
VH4011499
ViiV Healthcare
HIV Infections
06/24
06/24
NCT05585307: Study of Novel Antiretrovirals in Participants With HIV-1

Completed
1
49
US, RoW
bavtavirine, GS-5894, B/F/TAF, Biktarvy®, Standard of Care (Substudy 01), GS-1720, Standard of Care (Substudy 02), GS-6212, Standard of Care (Substudy 03)
Gilead Sciences
HIV-1-infection
03/24
03/24
NCT05244473: A Safety Study of Brentuximab Vedotin in Participants With HIV

Withdrawn
1
48
US
brentuximab vedotin, ADCETRIS, Placebo, ART
Seagen Inc.
Human Immunodeficiency Virus
05/24
05/24
NCT06430905: Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

Not yet recruiting
1
30
US
HB-502 and HB-501 alternating 2-vector therapy Dose Level 1, HB-502 and HB-501 alternating 2-vector therapy Dose Level 2, Placebo
Hookipa Biotech GmbH
Human Immunodeficiency Virus (HIV) Infection
11/25
11/25
C112, NCT06449196: Mosaic HIV-1 Envelope Trimer Immunogens Administered to People Living With HIV (PLWH) in Africa

Not yet recruiting
1
40
RoW
Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM), : Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM)
International AIDS Vaccine Initiative, Polymun Scientific GmbH
HIV
12/25
12/25
NCT05781542: Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

Active, not recruiting
1
46
US, RoW
sD-NP-GT8 DNA, IL-12 DNA, Trimer 4571, 3M-052-AF, Alum
National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network, The Wistar Institute, The Betty and Dale Bumpers Vaccine Research Center (VRC), Inovio Pharmaceuticals, Access to Advanced Health Institute (AAHI), Department of Health and Human Services
HIV Infections
08/24
08/25
NCT05406583: A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

Recruiting
1
36
US, RoW
Dolutegravir 0.5 mg/kg oral suspension, DTG, Dolutegravir 5 mg Dispersible Tablets
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
HIV
09/24
02/25
NCT03684655: Imaging Immune Activation in HIV by PET-MR

Recruiting
1
30
US
[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine), VisAcT
CellSight Technologies, Inc., National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco
HIV Infections
10/24
11/24
NCT04177355: Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

Active, not recruiting
1
127
US
BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571
National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network, International AIDS Vaccine Initiative, Access to Advanced Health Institute (AAHI), Dynavax Technologies Corporation, Fred Hutchinson Cancer Center
HIV Infections
11/24
11/24
NCT05144386: Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

Active, not recruiting
1
6
US
EBT-101
Excision BioTherapeutics
HIV-1-infection
05/25
05/25
NCT06033547: A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants

Recruiting
1
48
US
Cabotegravir Formulation F, Cabotegravir Formulation G
ViiV Healthcare
HIV Infections
07/25
07/25
HIVAC-FOUND, NCT05772286: Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted With MPLA Liposomes, in Healthy, HIV-Uninfected Adults

Recruiting
1
12
Europe
763SIP8/MPLA-5 vaccine
Fundacion Clinic per a la Recerca Biomédica, Polymun Scientific GmbH
Healthy
06/25
06/25
RV582, NCT05769569: Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission

Withdrawn
1
35
RoW
VRC07-523LS, VRC-HIVMAB075-00-AB, PGDM1400LS, N-803, Ad26.Mos4.HIV, MVA-BN-HIV, A244d11 gp120, ALFQ, Antiretroviral Therapy (ART)
Henry M. Jackson Foundation for the Advancement of Military Medicine, US Military HIV Research Program, Janssen Vaccines & Prevention B.V.
HIV-1-infection
07/25
07/25
AMC-105, NCT04139304: A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Recruiting
1
15
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine, LEUROCRISTINE, VCR, Vincrystine, Vincristine Sulfate, Kyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
AIDS Malignancy Consortium, National Cancer Institute (NCI), Janssen Scientific Affairs, LLC, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, AIDS and Cancer Specimen Resource, The Emmes Company, LLC
Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
07/25
08/27
NCT04820933: Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV

Recruiting
1
20
US
Doravirine 100 Mg, Descovy (200 mg emtricitabine + 10 mg tenofovir alafenamide fumarate)
University of Texas Southwestern Medical Center, Merck Sharp & Dohme LLC
HIV I Infection, Cardiovascular Risk Factor, Lipid Metabolism Disorders
09/25
09/25
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Recruiting
1
46
US
N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074
National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc.
HIV Infection
10/25
04/26
NCT05854381: To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

Recruiting
1
95
US, RoW
VIR-1388, Placebo
Vir Biotechnology, Inc., National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network
HIV I Infection
11/25
11/27
NCT04620291: Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults

Not yet recruiting
1
18
NA
UB-421 SC, Humanized dB4C7C22-6 monoclonal antibody
United BioPharma
HIV-1-infection
12/25
12/25
NCT06012136: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

Recruiting
1
160
US
VH4004280, Placebo, VH4011499
ViiV Healthcare
HIV Infections
05/26
05/26
NCT05143307: Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101

Enrolling by invitation
1
9
US
EBT-101
Excision BioTherapeutics
HIV-1-infection
01/37
04/37
NCT00046345: Atazanavir for HIV Infected Individuals: An Early Access Program

No Longer Available
N/A
US
Atazanavir (BMS-232632)
Bristol-Myers Squibb
HIV Infections
 
07/03
NCT00162227: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

No Longer Available
N/A
US
Efavirenz, Sustiva, BMS-561525
Bristol-Myers Squibb
HIV Infection
12/10
12/10
NCT00162188: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada

No Longer Available
N/A
Canada
Efavirenz, Sustiva, BMS-561525
Bristol-Myers Squibb
HIV Infection
12/10
12/10
NCT00801515: A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

No Longer Available
N/A
Canada
Maraviroc, Celsentri
ViiV Healthcare, Pfizer
HIV
07/11
07/11
NCT00595192: A Study of HIV-infected Subjects Initiating Anti-HIV Drugs for the First Time

Recruiting
N/A
35
US
Drexel University College of Medicine, National Institutes of Health (NIH), Argos Therapeutics
HIV Infections
08/11
 
NCT01776996: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc

No Longer Available
N/A
Europe, RoW
Continued Access Arm
ViiV Healthcare, GlaxoSmithKline
Infection, Human Immunodeficiency Virus
 
 
POPPY, NCT01737047 / 2012-003581-40: The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'

Active, not recruiting
N/A
1377
Europe
Imperial College London, Gilead Sciences, Janssen, LP, ViiV Healthcare, Bristol-Myers Squibb, Merck Sharp & Dohme LLC
HIV Positive, Ageing
01/18
12/21
CD02_EA, NCT02759042: An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study

No Longer Available
N/A
US
PRO 140, PRO140, CCR5 antagonist, Humanized monoclonal antibody to CCR5
CytoDyn, Inc., Amarex Clinical Research
HIV
 
 
NCT00992654: A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India

No Longer Available
N/A
NA
Open Label Treatment Access: Maraviroc, Maraviroc, Celsentri, Selzentry
ViiV Healthcare, Pfizer
Human Immunodeficiency Virus (HIV)
 
 
HIV, NCT04088916: Proviral DNA as a Target for -1 Resistance Analysis

Recruiting
N/A
1200
RoW
University of Chile, ViiV Healthcare
HIV/AIDS, HIV Infections, HIV Seropositivity, Viral Infection
09/19
12/22
GEN-AFRICA, NCT05685810: Genetic Determinants of Kidney Disease in People of African Ancestry With HIV

Active, not recruiting
N/A
3029
Europe
King's College Hospital NHS Trust, Guy's and St Thomas' NHS Foundation Trust, St George's University Hospitals NHS Foundation Trust, Lewisham and Greenwich NHS Trust, Royal Free Hospital NHS Foundation Trust, Central and North West London NHS Foundation Trust, Barts & The London NHS Trust, Chelsea and Westminster NHS Foundation Trust, Imperial College Healthcare NHS Trust, North Middlesex University Hospital NHS Trust, Brighton and Sussex University Hospitals NHS Trust, The Leeds Teaching Hospitals NHS Trust, Manchester University NHS Foundation Trust, Newcastle-upon-Tyne Hospitals NHS Trust, South Tees Hospitals NHS Foundation Trust, Africa Advocacy Foundation, Vanderbilt University, University of Cape Town, University of Pennsylvania, Medical Research Council, Guy's and St. Thomas' Charity, British HIV Association, Gilead Sciences
HIV Nephropathy, Kidney Injury, Kidney Diseases, Diabetes Mellitus, Obesity, Cardiovascular Diseases, Genetic Predisposition to Disease
01/20
01/30
PRESTIGIO, NCT04098315: Italian Registry of HIV-1 Infected Patients With Drug-RESistant Virus to Reverse Transcriptase Inhibitors, InteGrasE and Viral Protease.

Recruiting
N/A
300
Europe
REGISTER CREATION
Castagna Antonella, ViiV Healthcare
HIV-1-infection, Multi-Antiviral Resistance
03/20
12/28
NCT04350554: Pregnancy in Women With HIV Infection

Not yet recruiting
N/A
160
NA
Pregnancy
Carlos III Health Institute, Red Temática de Investigación Cooperativa en Sida, Merck Sharp & Dohme Corp.
HIV Infections, Pregnancy Related
09/20
06/21
MUTARESERVOIR, NCT04448158: Dynamics of Drug Resistance-associated Mutations in HIV-1 DNA Reverse Transcriptase Clearance During Effective Antiretroviral Therapy

Completed
N/A
79
Europe
Genotypic Resistance Test
Association de Recherche en Virologie et Dermatologie, ViiV Healthcare
HIV-1-infection
05/21
07/21
NCT03462810: GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV

Available
N/A
NA
cabotegravir, CAB, cabotegravir, CAB
ViiV Healthcare
Infection, Human Immunodeficiency Virus
 
 
BHVD, NCT01634607: Bone Health and Vitamin D Status

Completed
N/A
235
RoW
Thai Red Cross AIDS Research Centre, ViiV Healthcare, HIV Netherlands Australia Thailand Research Collaboration, Bamrasnaradura Infectious Diseases Institute, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Osteopenia, Vitamin D Deficiency, HIV Infection
07/21
02/23
NCT04453436: HIV Drug Resistance Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil

Not yet recruiting
N/A
2500
NA
Tenofovir Disoproxil, Lamivudine, Dolutegravir
Federal University of São Paulo, Gilead Sciences
HIV, Drug, Resistance
09/21
01/22
NCT04296331: HIV Jail POC-AgAB Testings

Completed
N/A
6613
US
POC, INSTI® rapid test, Ag/Ab, Ag/Ab: ARCHITECT® laboratory-based test, POC + Ag/Ab, INSTI® rapid test and ARCHITECT® laboratory-based test
Montefiore Medical Center, Emory University, Unity Health Care, Inc., National Institutes of Health (NIH)
HIV/AIDS
09/21
04/23
SCAPE-HIV, NCT05067400: SARS-CoV-2 (COVID-19) Antibody PrevalencE in an Adult London HIV Cohort

Completed
N/A
615
Europe
Royal Free Hospital NHS Foundation Trust, Roche Diagnostics
HIV-1-infection, SARS-CoV Infection, Covid19
06/23
06/23
NCT04089488: Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America

Completed
N/A
175
RoW
Medical Chart Review, Chart Review, Survey Administration
AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas
HIV Infection, Human Immunodeficiency Virus 1 Positive, Malignant Neoplasm, Recurrent Malignant Neoplasm
10/21
10/21
NCT03693040: Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP)

Active, not recruiting
N/A
100
US
Digital Health Feedback System
University of California, San Diego, National Institute of Mental Health (NIMH), Gilead Sciences, Proteus Digital Health, Inc.
HIV Prevention
12/21
12/22
NCT03706950: Post-approval Observational Study of Elpida® in the First Line Therapy for HIV-1 Infected Patients With Background Standard ART

Recruiting
N/A
2000
RoW
Elpida® + 2 NRTIs
Viriom
HIV-1-infection
12/21
12/22
NCT01567722: Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies

Terminated
N/A
114
US
DNA analysis, RNA analysis, gene expression analysis, polymorphism analysis, biologic sample preservation procedure, flow cytometry, medical chart review
AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, AIDS and Cancer Specimen Resource, University of Arkansas
Lung Cancer, Lymphoma
01/22
01/22
EvvA, NCT04593979: ANRS 12406 Study

Recruiting
N/A
289
RoW
ANRS, Emerging Infectious Diseases, Hospital Laquinitinie de Douala, Franceville International Center for Medical Research, Gabon, Institut Pasteur
HIV-1-infection
01/22
01/22
PREDIACC, NCT04208711: Role of PLA2G1B During HIV Infection

Recruiting
N/A
15
Europe
biological sample
Diaccurate SAS, CIC 1417 Cochin-Pasteur
HIV Infections
03/22
03/22
CORIA, NCT04354818: Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia

Active, not recruiting
N/A
27
RoW
Kirby Institute, St Vincent's Hospital, Sydney, Garvan Institute of Medical Research, Westmead Hospital, Sydney, Australia, Blacktown Hospital, Sydney, Australia, Holdsworth House Medical Practice, Royal North Shore Hospital, Melanoma Institute Australia, Prince of Wales Hospital, Sydney, Gilead Sciences, Cancer Institute NSW, Cancer Council New South Wales, Positive Life NSW, St George Hospital, Australia, Liverpool Hospital, Sydney
HIV-1-infection, Cancer, Primary Immune Deficiency Disorder, Immunosuppression Disorders, COVID-19
04/22
04/22
PROBI, NCT04788784: Patient-Reported Outcomes HIV BItherapy

Recruiting
N/A
250
Europe
University Paris 7 - Denis Diderot, ViiV Healthcare
HIV/AIDS and Infections, Patient Preference
05/22
08/22
NCT04048850: Zepatier in Patients With Substance Use

Active, not recruiting
N/A
25
US
Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER], Zepatier
University of Illinois at Chicago, Merck Sharp & Dohme LLC
Hepatitis C, Hiv, Coinfection, HIV, Substance Use Disorders
06/22
12/22
NCT04887675: Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI

Recruiting
N/A
120
RoW
MRI
University of Novi Sad, Merck Sharp & Dohme Corp.
HIV I Infection, HIV Associated Lipodystrophy, Metabolic Syndrome, Aging
06/22
10/22
NCT04233047: Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1)

Available
N/A
NA
Fostemsavir
ViiV Healthcare
HIV Infections
 
 
OPTICARE, NCT03799276: Optimisation of Care in Vulnerable HIV Infected Individuals

Completed
N/A
200
Europe
Opticare study
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida, ViiV Healthcare, Institut de Sante Publique, d'Epidemiologie et de Developpement
HIV Infections
06/22
12/23
NCT04633200: Mhealth for PrEP Adherence by Young Adult MSM, Phase 2

Completed
N/A
108
US
DOT mobile app
Environment and Health Group, Inc.
Hiv
06/22
07/22
NCT04863261: Cabenuva Injection Tracking in CHORUS

Completed
N/A
37
US
Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App
Epividian, AIDS Healthcare Foundation, ViiV Healthcare
HIV Infections
07/22
07/22
NCT04240691: Instacare - Rapid ART Initiation Among Persons With HIV and Out of Care

Active, not recruiting
N/A
124
US
60-Minutes-For-Health, Time-and-Attention Control Session
University of California, San Diego, Gilead Sciences
Hiv, HIV Infections
09/22
11/23
 

Download Options